To identify and address practical, ethical, and regulatory issues that arise from the use, and potential misuse, of the expanded access pathway by various CGT stakeholders. The Working Group will develop informed perspectives on expanded access that will help ISCT as it generates educational resources that promote innovation in translational research while upholding the highest ethical standards.
Patricia J. Zettler, JDJanuary 2022 - Present
The Ohio State UniversityUnited States
Aaron Levine, PhD, MPhilGeorgia Institute of TechnologyUnited States
Bambi Grilley, RPh, RAC, CIP, CCRC, CCRPBaylor College of MedicineUnited States
Beth Roxland, JD, MBioethics Roxland Consultants Ltd. United States
Karen Nichols, Esq.Vertex PharmaceuticalsUnited States
Laertis Ikonomou, PhDThe State University of New York at BuffaloUnited States
Leigh Turner, PhDUniversity of California IrvineUnited States
Wilson Bryan, MDAppointed FDA representativeDirector of the Office of Tissues and Advanced TherapiesUnited States
View All Committees